

Vanda Pharmaceuticals Inc.
Form 8-K
July 30, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2013

VANDA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other Jurisdiction

of Incorporation)

001-34186
(Commission

File No.)

03-0491827
(IRS Employer

Identification No.)

Edgar Filing: Vanda Pharmaceuticals Inc. - Form 8-K

2200 Pennsylvania Avenue NW

Suite 300E

Washington, DC
(Address of Principal Executive Offices)

20037
(Zip Code)

Registrant's telephone number, including area code: (202) 734-3400

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On July 29, 2013, Vanda Pharmaceuticals Inc. (Vanda) issued a press release announcing the U.S. Food and Drug Administration 's acceptance and priority review of Vanda 's New Drug Application for tasimelteon for the treatment of Non-24-Hour Disorder in the totally blind. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.	Description
99.1	Press Release of Vanda Pharmaceuticals Inc. dated July 29, 2013.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VANDA PHARMACEUTICALS INC.

By: /s/ JAMES P. KELLY

Name: James P. Kelly

Title: Senior Vice President, Chief Financial
Officer, Secretary, and Treasurer

Dated: July 29, 2013